Abstract
Background: The survival benefit of Implantable cardioverter defibrillator (ICD) in ischemic cardiomyopathy with an ejection fraction (EF) of ≤35% is well established. However, there remains controversy regarding its benefit in non-ischemic cardiomyopathy (NICM). We performed a meta-analysis
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
